

Docket No. JAB1461USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John Paul McGee et al.

Serial No. : 09/868,991

Art Unit: 1615

Filed

: July 26, 2001

Examiner: B.A. Fubara

For

: CONTROLLED-RELEASE GALANTAMINE COMPOSITION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 21, 2005
(Date of Deposit)

Mary A. Appollina (Name of applicant, assignee, or Registered Representative)

/Mary A. Appollina/
(Signature)
October 21, 2005

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on August 4, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

in accordance with \$1.97(b), since this information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set fortl
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \Box the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
·

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

Statement in Accordance with §1.97(e	:)
(attached); or	
Please charge Deposit Account No. 10	ı –
0750/JAB1461/MAA the fee of \$180.00	as set forth
in §1.17(p).	
In accordance with §1.97(d), this Informa	tion
Disclosure Statement is being filed after the mailing	ng date of
either a Final Action under §1.113 or a Notice of A	llowance
under $\S1.311$ but before the payment of the Issue Fe	ee.
Applicant(s) hereby petition(s) for consideration of	f this
Information Disclosure Statement. Included are: St	tatement in
Accordance with §1.97(e) as set forth below and the	fee of
\$180.00 as set forth in §1.17(p).	
	•
Copies of each of the references listed or	n the
attached Form PTO-1449 are enclosed herewith.	
Copies of references listed on the attache	ed Form PTO-
1449 are enclosed herewith EXCEPT THAT:	
In view of the voluminous nature of	references
[list as appropriate], and the likel	ihood that
these references are available to the	
copies are not enclosed herewith.	•
<pre>If any of the foregoing publications</pre>	are not
available to the Examiner, Applicant	will
endeavor to supply copies at the Exam	
request.	
☐ Copies of only foreign patent documents ar	nd non-
patent literature are enclosed in accordance with 37	
(a) (2).	

 \square There are no listed references which are not in the English language. English translations are provided for JP 10-231242 and JP 9-165329. Copies of English equivalents are provided for: JP 9-295933 (EP 793 959); JP 6-507617 (WO 92/20328); JP 8-505633 (US 5,643,905); and WO 97/03987 (US 5,958,903). The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from П corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1461USNP/MAA. This form is submitted in triplicate. Respectfully submitted, /Mary A. Appollina/ Mary A. Appollina Reg. No. 34,087 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3742
DATED: October 21, 2005



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 3

decirection of information diffess it displays a valid Come control fidinger.				
Application Number	09/868,991			
Filing Date	July 26, 2001			
First Named Inventor	John Paul McGee et al.			
Group Art Unit	1615			
Examiner Name	B.A. Fubara			
Attorney Docket Number	JAB1461USNP			

U.S. PATENT DOCUMENTS

Initials	Cite	U.S. Patent Document Kind C		Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or
	No.1	Number (if kn	own) of Cited Document	mm-dd-yyyy	relevant figures appear
		5,151,273	Korsatko-Wabnegg et al.	09/29/1992	
		5,519,017	Klaus Opitz	05/21/1996	
		5,589,475	Snorrason	12/31/1996	

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Initiale	Cite No. ¹	Office ³	Number⁴ Kind	lCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		JP	6-507617		Burgmann Ole et al.	09-01-1994	• ,	
		JP	9-165329		Asahi Kasei Kogyo K.K.	06-24-1997		
·		JP	10- 231242		Taiyo Yakuhin Kogyo K.K.	09-02-1998	·	
		JP	9-295933		Takeda Yakuhin Kogyo K.K.	11-18-1997		
		JP	8-505633		H.F. Altzneimittel Folschung GmbH	06-18-1996		
		wo	97/47304		Janssen Pharmaceutica N.V.	12-18-1997		
		wo	98/55148		Janssen Pharmaceutica N.V.	12-10-1998		

Examiner	 Date	
Signature	Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 3

a collection of information unless it displays a valid ONIB control number:				
Application Number	09/868,991			
Filing Date	July 26, 2001			
First Named Inventor	John Paul McGee et al.			
Group Art Unit	1615			
Examiner Name	B.A. Fubara			
Attorney Docket Number	JAB1461USNP			

				U.S. PATENT DOCUMENTS			
		U.S. Patent Do	cument		Date of Publication	Pages, Columns, Lines,	
Examiner Initials		Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
			·				
					·	·	

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document where relevant of Cited Document Name of Patentee or passages or relevant Examiner mm-dd-yyyy Applicant of Cited Document figures appear Initials KindCode⁵ Office³ Number⁴ No.1 07/06/2000 00/38686 Janssen Pharmaceutica WO N.V. 02/06/1997 Societe De Conseils De WO 97/03987 Recherches Et D'Applications Scientifiques Davis, Bonnie M. 05/06/1999 WO 99/21561 04/19/1995 ΕP 0648771 Α1 Hoechst-Rousel **Pharmacueticals** Incorporated 05/17/1995 ΕP 0653427 B1 **Aventis Pharmaceuticals** Inc. 0879596 A2 Snorasson, Enir 11/25/1998 EΡ Reykjavik

					
Examiner		0	ate		
Signature	•		Considered		

OCT 2.4 2005 W

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 3 of 3

collection of information diffess it displays a valid OMB control number.					
Application Number	09/868,991				
Filing Date	July 26, 2001				
First Named Inventor	John Paul McGee et al.				
Group Art Unit	1615				
Examiner Name	B.A. Fubara				
Attorney Docket Number	JAB1461USNP				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Chiao, C.S.L., et al. "Sustained-Release Drug Delivery Systems." Remington: The Science and Practice of Pharmacy, Gennaro, A.R., ed. 1995, pp. 1660 & 1661	
1		Conte, U, et al. Press Coated Tablets For Time-Programmed Release Of Drugs, Biomaterials. 1993, VOL. 14, No. 13 Pages 1017-1023, Entire Document	
		Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, pgs. 161-176, Chapter 8 (eds. Joel G. Hardman and Lee E. Limbird, McGraw-Hill, 1996).	
	-		
		·	
		, and the second	

		 ·
Examiner	 Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.